165 related articles for article (PubMed ID: 22965827)
1. Possible improvement of survival with use of zoledronic acid in patients with bone metastases from renal cell carcinoma.
Yasuda Y; Fujii Y; Yuasa T; Kitsukawa S; Urakami S; Yamamoto S; Yonese J; Takahashi S; Fukui I
Int J Clin Oncol; 2013 Oct; 18(5):877-83. PubMed ID: 22965827
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases secondary to advanced renal cell carcinoma: application to France, Germany, and the United Kingdom.
Botteman MF; Meijboom M; Foley I; Stephens JM; Chen YM; Kaura S
Eur J Health Econ; 2011 Dec; 12(6):575-88. PubMed ID: 20809091
[TBL] [Abstract][Full Text] [Related]
3. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity.
Hirsh V; Major PP; Lipton A; Cook RJ; Langer CJ; Smith MR; Brown JE; Coleman RE
J Thorac Oncol; 2008 Mar; 3(3):228-36. PubMed ID: 18317064
[TBL] [Abstract][Full Text] [Related]
4. Skeletal complications and survival in renal cancer patients with bone metastases.
Woodward E; Jagdev S; McParland L; Clark K; Gregory W; Newsham A; Rogerson S; Hayward K; Selby P; Brown J
Bone; 2011 Jan; 48(1):160-6. PubMed ID: 20854942
[TBL] [Abstract][Full Text] [Related]
5. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.
Henk HJ; Kaura S
J Med Econ; 2012; 15(1):175-84. PubMed ID: 22017235
[TBL] [Abstract][Full Text] [Related]
6. Prospective observational study of treatment pattern, effectiveness and safety of zoledronic acid therapy beyond 24 months in patients with multiple myeloma or bone metastases from solid tumors.
Van den Wyngaert T; Delforge M; Doyen C; Duck L; Wouters K; Delabaye I; Wouters C; Wildiers H
Support Care Cancer; 2013 Dec; 21(12):3483-90. PubMed ID: 23955094
[TBL] [Abstract][Full Text] [Related]
7. Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases.
Tunn UW; Stenzl A; Schultze-Seemann W; Strauss A; Kindler M; Miller K; Wirth MP; Zantl N; Schulze M; May C; Ruebel A; Birkholz K; Gruenwald V
Can J Urol; 2012 Jun; 19(3):6261-7. PubMed ID: 22704310
[TBL] [Abstract][Full Text] [Related]
8. Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases: a randomized first-line phase II trial.
Broom RJ; Hinder V; Sharples K; Proctor J; Duffey S; Pollard S; Fong PC; Forgeson G; Harris DL; Jameson MB; O'Donnell A; North RT; Deva S; Hanning FJ; Grey A; Findlay MP
Clin Genitourin Cancer; 2015 Feb; 13(1):50-8. PubMed ID: 25163397
[TBL] [Abstract][Full Text] [Related]
9. Possible anti-tumor activity of initial treatment with zoledronic acid with hormonal therapy for bone-metastatic prostate cancer in multicenter clinical trial.
Uemura H; Yanagisawa M; Ikeda I; Fujinami K; Iwasaki A; Noguchi S; Noguchi K; Kubota Y;
Int J Clin Oncol; 2013 Jun; 18(3):472-7. PubMed ID: 22491982
[TBL] [Abstract][Full Text] [Related]
10. Assessment of zoledronic acid treatment patterns and clinical outcomes in patients with bone metastases from genitourinary cancers.
Henk HJ; Kaura S
J Med Econ; 2012; 15(1):185-94. PubMed ID: 22168786
[TBL] [Abstract][Full Text] [Related]
11. A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer.
Zaghloul MS; Boutrus R; El-Hossieny H; Kader YA; El-Attar I; Nazmy M
Int J Clin Oncol; 2010 Aug; 15(4):382-9. PubMed ID: 20354750
[TBL] [Abstract][Full Text] [Related]
12. The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis.
Zarogoulidis K; Boutsikou E; Zarogoulidis P; Eleftheriadou E; Kontakiotis T; Lithoxopoulou H; Tzanakakis G; Kanakis I; Karamanos NK
Int J Cancer; 2009 Oct; 125(7):1705-9. PubMed ID: 19521984
[TBL] [Abstract][Full Text] [Related]
13. Comparison of skeletal complications and treatment patterns associated with early vs. delayed zoledronic acid therapy in multiple myeloma.
Wu EQ; Bensimon AG; Marynchenko M; Namjoshi M; Guo A; Yu AP; Ericson SG; Raje N
Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):326-35. PubMed ID: 21700528
[TBL] [Abstract][Full Text] [Related]
14. Use of bisphosphonates in metastatic breast cancer: single institution review at the Dr. H. Bliss Murphy Cancer Centre.
Murphy L; McCarthy J; McCrate F; Laing K; Powell E; Seal M; Edwards S
Support Care Cancer; 2013 Jun; 21(6):1557-60. PubMed ID: 23334521
[TBL] [Abstract][Full Text] [Related]
15. Zoledronic acid in patients with stage IIIA/B NSCLC: results of a randomized, phase III study.
Scagliotti GV; Kosmidis P; de Marinis F; Schreurs AJM; Albert I; Engel-Riedel W; Schallier D; Barbera S; Kuo HP; Sallo V; Perez JR; Manegold C
Ann Oncol; 2012 Aug; 23(8):2082-2087. PubMed ID: 22730101
[TBL] [Abstract][Full Text] [Related]
16. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.
Lipton A; Small E; Saad F; Gleason D; Gordon D; Smith M; Rosen L; Kowalski MO; Reitsma D; Seaman J
Cancer Invest; 2002; 20 Suppl 2():45-54. PubMed ID: 12442349
[TBL] [Abstract][Full Text] [Related]
17. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion.
Rosen LS; Gordon DH; Dugan W; Major P; Eisenberg PD; Provencher L; Kaminski M; Simeone J; Seaman J; Chen BL; Coleman RE
Cancer; 2004 Jan; 100(1):36-43. PubMed ID: 14692022
[TBL] [Abstract][Full Text] [Related]
18. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma.
Lipton A; Zheng M; Seaman J
Cancer; 2003 Sep; 98(5):962-9. PubMed ID: 12942563
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acid.
Saad F; Segal S; Eastham J
Eur Urol; 2014 Jan; 65(1):146-53. PubMed ID: 22633317
[TBL] [Abstract][Full Text] [Related]
20. Zoledronic acid use in patients with bone metastases from renal cell carcinoma or bladder cancer.
Saad F; Eastham JA
Semin Oncol; 2010 Jun; 37 Suppl 1():S38-44. PubMed ID: 20682371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]